<DOC>
	<DOCNO>NCT02362035</DOCNO>
	<brief_summary>This study evaluate safety , pharmacodynamics ( PD ) , efficacy acalabrutinib pembrolizumab hematologic malignancy .</brief_summary>
	<brief_title>ACP-196 ( Acalabrutinib ) Combination With Pembrolizumab , Treatment Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Main Diagnosis hematologic malignancy document medical record histology base criterion establish World Health Organization ( WHO ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . Agreement use contraception study 90 day last dose ACP196 120 day last dose pembrolizumab , sexually active able bear beget child . Completion therapy ( include surgery , radiotherapy , chemotherapy , immunotherapy , investigational therapy ) treatment cancer ≥ 4 week start study therapy . ANC ≥ 0.5 x 10^9/L platelet count ≥ 50 x 10^9/L unless due disease involvement bone marrow . Main A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism study drug , put study outcome undue risk . Central nervous system ( CNS ) involvement lymphoma/leukemia Any therapeutic antibody within 4 week first dose study drug . Total bilirubin &gt; 1.5 x ULN ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3.0 x ULN . Estimated creatinine clearance &lt; 30 mL/min , calculate use formula Cockcroft Gault ( 140Age ) • Mass ( kg ) / ( 72 • creatinine mg/dL ) ; multiply 0.85 female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>B-Cell Malignancies</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Follicular</keyword>
	<keyword>Waldenstrom</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>hairy cell leukemia</keyword>
	<keyword>B cell acute lymphoid leukemia</keyword>
	<keyword>Acalabrutinib</keyword>
	<keyword>ACP-196</keyword>
</DOC>